Supplementary Online Content


eFigure 1. Anti-AChR Antibody Levels During Extended Follow-up

eFigure 2. Serum Cytokine Levels

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1. Anti-AChR Antibody Levels During Extended Follow-up

![Graph showing anti-AChR antibody levels during different time points: Pre-rituximab, Post last cycle, and Last follow up.](image-url)
(A) Anti-AChR antibody levels (nmol/L) in seven patients who have not had a relapse of disease. A significant reduction in antibody levels (from the pre-treatment value) was noted in this subgroup of patients after the last cycle of rituximab (p<0.05) and the levels remained low at the time of last follow up. (B) Anti-AChR antibody levels (nmol/L) in seven of the nine patients who experienced a relapse of disease where autoantibody data was available. Of these, five patients received additional cycles of rituximab post relapse. The change in antibody levels at relapse was not statistically significant (p>0.05) after the initial reduction (p<0.05) observed with rituximab therapy.

*Antibody level in one patient who experienced a second relapse 2 years after the first. Follow up levels unavailable.
eFigure 2. Serum Cytokine Levels

A

Serum concentrations of Resistin (A) and VEGF (B) in four patients with active disease before initiation of rituximab, and ten healthy donors

p = 0.45

p = 0.83

© 2016 American Medical Association. All rights reserved.